Source: The Pharma Letter

STIVARGA: BRIEF-Bayer's Stivarga approved in second-line HCC in China

The China Food and Drug Administration has approved Stivarga (regorafenib) as a treatment for hepatocellular...

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
1-25
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100



STIVARGA's headquarters is in Whippany, New Jersey. STIVARGA has a revenue of $10M, and 10 employees.